Effects of ipriflavone on bone remodeling in primary hyperparathyroidism

Gianfranco Mazzuoli; Elisabetta Romagnoli; Vincenzo Carnevale; Antonella Scarda; Liliana Scarnecchia; Maria Teresa Pacitti; Rossana Rosso; Salvatore Minisola

doi:10.1016/0169-6009(92)90863-9

Effects of ipriflavone on bone remodeling in primary hyperparathyroidism

Gianfranco Mazzuoli, Elisabetta Romagnoli, Vincenzo Carnevale, Antonella Scarda, Liliana Scarnecchia, Maria Teresa Pacitti, Rossana Rosso, Salvatore Minisola

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean ± SD age 56 ± 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.

Original language	English
Journal	Bone and Mineral
Volume	19
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/0169-6009(92)90863-9
Publication status	Published - 1992

Keywords

Bone remodeling
Ipriflavone
Primary hyperparathyroidism

ASJC Scopus subject areas

Biochemistry
Endocrinology
Surgery

Access to Document

10.1016/0169-6009(92)90863-9

Cite this

@article{364a01f46f8e41d4b2f1c0c61b88c174,

title = "Effects of ipriflavone on bone remodeling in primary hyperparathyroidism",

abstract = "The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean ± SD age 56 ± 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.",

keywords = "Bone remodeling, Ipriflavone, Primary hyperparathyroidism",

author = "Gianfranco Mazzuoli and Elisabetta Romagnoli and Vincenzo Carnevale and Antonella Scarda and Liliana Scarnecchia and Pacitti, {Maria Teresa} and Rossana Rosso and Salvatore Minisola",

year = "1992",

doi = "10.1016/0169-6009(92)90863-9",

language = "English",

volume = "19",

journal = "Bone and Mineral",

issn = "0169-6009",

publisher = "Elsevier BV",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Effects of ipriflavone on bone remodeling in primary hyperparathyroidism

AU - Mazzuoli, Gianfranco

AU - Romagnoli, Elisabetta

AU - Carnevale, Vincenzo

AU - Scarda, Antonella

AU - Scarnecchia, Liliana

AU - Pacitti, Maria Teresa

AU - Rosso, Rossana

AU - Minisola, Salvatore

PY - 1992

Y1 - 1992

N2 - The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean ± SD age 56 ± 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.

AB - The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean ± SD age 56 ± 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.

KW - Bone remodeling

KW - Ipriflavone

KW - Primary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=0026803194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026803194&partnerID=8YFLogxK

U2 - 10.1016/0169-6009(92)90863-9

DO - 10.1016/0169-6009(92)90863-9

M3 - Article

C2 - 1422317

AN - SCOPUS:0026803194

VL - 19

JO - Bone and Mineral

JF - Bone and Mineral

SN - 0169-6009

IS - SUPPL. 1

ER -

Effects of ipriflavone on bone remodeling in primary hyperparathyroidism

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this